BiotechTube

UB-612

Phase 2/3Withdrawn
0 watching 0 views this week⚡ Active
57
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid-19

Conditions

Covid-19, SARS-CoV-2, Coronavirus

Trial Timeline

Feb 1, 2021 → Mar 22, 2023

NCT ID
NCT04683224

About UB-612

UB-612 is a phase 2/3 stage product being developed by Vaxxinity for Covid-19. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04683224. Target conditions include Covid-19, SARS-CoV-2, Coronavirus.

Hype Score Breakdown

Clinical
22
Activity
15
Company
2
Novelty
7
Community
8

Clinical Trials (3)

NCT IDPhaseStatus
NCT04967742Phase 1Completed
NCT04683224Phase 2/3Withdrawn
NCT04545749Phase 1Completed

Competing Products

20 competing products in Covid-19

See all competitors
ProductCompanyStageHype Score
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
51
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Gimsilumab + PlaceboRoivant SciencesPhase 2
49
Icosapent ethylAmarin CorporationPhase 2
44
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
77
InfliximabCelltrionPhase 2
52
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
77
Enzalutamide PillAstellas PharmaPhase 2
52
S-892216 + PlaceboShionogiPhase 2
52
S-892216 + CarbamazepineShionogiPhase 1
33
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
DesidustatZydus LifesciencesPhase 2
52
LY3819253 + PlaceboEli LillyPhase 1
33
Bamlanivimab + Etesevimab + Placebo + VIR-7831 + BebtelovimabEli LillyPhase 2
52
BamlanivimabEli LillyPhase 2
52
LY3127804 + PlaceboEli LillyPhase 2
52
Baricitinib + PlaceboEli LillyPhase 3
77
BamlanivimabEli LillyPre-clinical
23
LY3819253 + Placebo + RemdesivirEli LillyPhase 3
77
LY3819253 + LY3832479 + LY3853113 + PlaceboEli LillyPhase 2/3
65

Other Products from Vaxxinity

UB-612 + BNT162b2 vaccine + ChAdOx1-S vaccine + Sinopharm BIBPPhase 3
69
UB-612 + PlaceboPhase 2
44
UB-312 + PlaceboPhase 1
25
UB-612Phase 1
25
UB-612Phase 1
25